Posted on Sunday, 06/Jan/2013 Posted by admin

Diurnal is pleased to report that the first patient has been enrolled into the CATCH (Chronocort As Treatment for Congenital adrenal Hyperplasia) trial.  The CATCH trial is a Phase 2 study in patients suffering from Congenital Adrenal Hyperplasia and is being run by the National Institute of Health (NIH), Maryland, US under a Cooperative Research and Development Agreement (CRADA).  The title of the CRADA is "Age-Appropriate Hydrocortisone Formulations for the Treatment of Adrenal Insufficiency including Congenital Adrenal Hyperplasia" and the research aims to investigate the use of Chronocort® (circadian hydrocortisone) in patients who suffer from these rare (orphan) diseases.

Martin Whitaker, Chief Executive Officer, Diurnal, stated:

"We are delighted that the CATCH trial has started at the National Institute of Health.  This is a significant milestone for Diurnal.  The CATCH trial will demonstrate the efficacy of Chronocort in patients for the first time"   


For further information please contact:

Martin Whitaker, PhD (Chief Executive Officer)
+44 (0) 871 716 8848